ESMO 2019 | Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results

Antonio González Martín

Antonio González Martín, MD, Clínica Universidad de Navarra, Madrid, Spain, presents results from the Phase III PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016) of niraparib in newly diagnosed advanced ovarian cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video